Research Specifications
- INN Name:
- Semaglutide
- CAS Number:
- 910463-68-2
- Molecular Weight:
- 4113.6 Da
- Side Chain:
- C18 fatty acid (albumin binding, ~7-day half-life)
- Form:
- Lyophilized powder
- Purity:
- ≥98% (HPLC verified)
- Storage:
- −20°C long-term / 4°C up to 4 weeks reconstituted
- Price per mg:
- $10.00
GLP-1 S 10mg
The original GLP-1 breakthrough. STEP-1 trial: 14.9% mean body weight reduction. The proven foundation of incretin-based research.
−14.9%
Mean Weight Reduction
STEP-1, 2.4mg/week (NEJM 2021)
94%
Homology to Human GLP-1
Sequence alignment
4113 Da
Molecular Weight
NCBI PubChem
Receptor Targets
GLP-1 Receptor Agonism: The Incretin Foundation
Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist with 94% homology to human GLP-1 and a C18 fatty acid side chain for albumin binding (half-life ~7 days, enabling once-weekly dosing). GLP-1R activation reduces appetite via hypothalamic signaling, slows gastric emptying, enhances glucose-stimulated insulin secretion, and suppresses glucagon. It is the reference compound against which all newer dual and triple agonists are compared.
Research Highlights
STEP-1 Trial (NEJM 2021)
1,961 participants at 2.4mg/week for 68 weeks. Mean weight reduction of 14.9% (vs 2.4% placebo). 70% of participants achieved ≥10% weight loss. The STEP program established GLP-1 agonism as a viable pharmacological approach to obesity management, setting the baseline for subsequent dual and triple agonist research.
SUSTAIN-6 Cardiovascular Outcomes
The SUSTAIN-6 CVOT trial demonstrated Semaglutide reduced major adverse cardiovascular events (MACE) by 26% vs placebo. The SELECT trial (2023) further confirmed 20% MACE reduction in people without diabetes — establishing cardiovascular benefits independent of glucose control.
Reference Compound Status
Semaglutide serves as the active comparator in most newer GLP-1 class research. SURPASS-2 used Semaglutide 1mg as the comparator for Tirzepatide. Understanding Semaglutide's mechanism is foundational to understanding the incremental benefits of dual and triple agonism.
Research FAQ
How does Semaglutide work?
Why would a researcher choose Semaglutide over Tirzepatide or Retatrutide?
What is the difference between Semaglutide doses in research?
Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.
Price Comparison
| Supplier | Purity | Price | Shipping |
|---|---|---|---|
| Apollo (via ClavTides) | >98% HPLC | $99.99 | Free over $200 |
| Generic Research Suppliers | Varies (often <95%) | Similar–Higher | Varies |
| Pharmaceutical (Rx only) | Pharmaceutical grade | Not available for research | Rx required |
Related Products
GLP-1 S 5mg
Synthetic peptide derivative structurally derived from human glucagon-like peptide-1 (GLP-1), modified to enhance stability. Supplied as lyophilized powder for laboratory research applications.
GLP-1 S 15mg
Synthetic peptide derivative structurally derived from human glucagon-like peptide-1 (GLP-1), modified to enhance stability. Supplied as lyophilized powder for laboratory research applications.
GLP-3 R 10mg
Retatrutide is a synthetic peptide analog incorporating structural modifications designed to enhance stability. Supplied as lyophilized powder for laboratory research applications.
GLP-1 S 10mg
$99.99